Lung

, Volume 190, Issue 3, pp 283–290 | Cite as

Serum Cystatin C and Emphysema: Results from the National Health and Nutrition Examination Survey (NHANES)

Article

Abstract

Background

Cystatin C (CysC) is a potent nonorgan-specific cysteine protease inhibitor and may contribute to elastolysis and tissue destruction by a mechanism of protease–antiprotease imbalance. Given the prevalence of CysC in the serum of smokers and its role in tissue destruction, we aimed to evaluate the association between CysC and emphysema.

Methods

Pooled cross-sectional data from the National Health and Nutrition Examination Survey 1999–2002 were used. Emphysema and chronic bronchitis were defined by a self-reported history ascertained using standardized questionnaires. Active smokers were defined as self-reported current smokers or measured serum cotinine ≥10 ng/mL. Nonactive smokers with a serum cotinine level >0.05 ng/mL were defined as environmental tobacco smoke (ETS)-exposed.

Results

The prevalence (95% CI) of emphysema was 1.3% (range = 0.9–1.8%). The mean (SE) CysC level in the emphysema group was significantly higher than in normal controls [1,139 (22) vs. 883 (8) μg/L; p = 0.001]. Upon stratification of the study population by C-reactive protein (CRP) concentrations, we demonstrated a progressive increase in the mean serum CysC level with serially increasing CRP concentrations. Active smokers with emphysema had 115.4 (46.5) μg/L higher mean (SE) CysC levels than the normal controls (p < 0.001). Upon adjusted analysis, we observed that nonactive smokers with significant ETS exposure had 31.2 (15.2) μg/L higher mean (SE) serum CysC levels as compared to ETS unexposed nonactive smokers (p = 0.04).

Conclusion

In a large representative noninstitutionalized US population, we demonstrated an association between emphysema and serum CysC. Active smokers with emphysema had significantly higher CysC levels. These findings suggest that CysC may play a role in the pathogenesis of smoking-related emphysema.

Keywords

Cystatin C Emphysema Chronic bronchitis Chronic obstructive pulmonary disease Smoking National Health and Nutrition Examination Survey 

References

  1. 1.
    Jannoff A, Sloan B, Weinbaum G et al (1977) Experimental emphysema induced with purified human neutrophil elastase: tissue localization of the instilled protease. Am Rev Respir Dis 115:461–478Google Scholar
  2. 2.
    Owen CA, Campbell EJ (1999) The cell biology of leukocyte-mediated proteolysis. J Leukoc Biol 65:137–150PubMedGoogle Scholar
  3. 3.
    Lesser M, Padilla ML, Cardozo C (1992) Induction of emphysema in hamsters by intratracheal instillation of cathepsin B. Am Rev Respir Dis 145:661–668PubMedGoogle Scholar
  4. 4.
    Chughtai B, O’Riordan TG (2004) Potential role of inhibitors of neutrophil elastase in treating diseases of the airway. J Aerosol Med 17:289–298PubMedCrossRefGoogle Scholar
  5. 5.
    Chua F, Laurent GJ (2006) Neutrophil elastase: mediator of extracellular matrix destruction and accumulation. Proc Am Thorac Soc 3:424–427PubMedCrossRefGoogle Scholar
  6. 6.
    Lungarella G, Cavarra E, Lucattelli M, Martorana PA (2008) The dual role of neutrophil elastase in lung destruction and repair. Int J Biochem Cell Biol 40:1287–1296PubMedCrossRefGoogle Scholar
  7. 7.
    Owen CA (2008) Roles for proteinases in the pathogenesis of chronic obstructive pulmonary disease. Int J Chronic Obstr Pulm Dis 3:253–268Google Scholar
  8. 8.
    Abboud RT, Vimalanathan S (2008) Pathogenesis of COPD. Part 1. The role of protease–antiprotease imbalance in emphysema. Int J Tuberc Lung Dis 12:361–367PubMedGoogle Scholar
  9. 9.
    Kos J, Lah TT (1998) Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis, and therapy in cancer. Oncol Rep 5:1349–1361PubMedGoogle Scholar
  10. 10.
    Chapman HA, Stone OL (1984) Comparison of live human neutrophils and alveolar macrophage elastolytic activity in vitro. Relative resistance of macrophage elastolytic activity to serum and alveolar proteinase inhibitors. J Clin Invest 74:1693–1700PubMedCrossRefGoogle Scholar
  11. 11.
    Abbott DE, Margaryan NV, Jeruss JS et al (2010) Reevaluating cathepsin D as a biomarker for breast cancer: serum activity levels versus histopathology. Cancer Biol Ther 9:23–30PubMedCrossRefGoogle Scholar
  12. 12.
    Meng L, Yang Y, Qi LT, Wang XJ, Xu GB, Zhang BW (2011) Elevated serum cystatin C is an independent predictor of cardiovascular events in people with relatively normal renal function. J Nephrol. doi:10.5301/jn.5000020 PubMedGoogle Scholar
  13. 13.
    Bevc S, Hojs R, Ekart R, Gorenjak M, Puklavec L (2011) Simple cystatin C formula compared to sophisticated CKD-EPI formulas for estimation of glomerular filtration rate in the elderly. Ther Apher Dial 15:261–268PubMedCrossRefGoogle Scholar
  14. 14.
    Kottgen A, Selvin E, Stevens LA et al (2008) Serum cystatin C in the United States: the third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 51:385–394PubMedCrossRefGoogle Scholar
  15. 15.
    Kyhse-Andersen J, Schmidt C, Nordin G et al (1994) Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 40:1921–1926PubMedGoogle Scholar
  16. 16.
    Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226PubMedCrossRefGoogle Scholar
  17. 17.
    Zore I, Krasovec M, Cimerman N et al (2001) Cathepsin B/Cystatin C complex levels in sera from patients with lung and colorectal cancer. Biol Chem 382:805–810PubMedCrossRefGoogle Scholar
  18. 18.
    Poteryaeva ON, Falameyeva OV, Korolenko TA et al (2000) Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. Drugs Exp Clin Res 26:301–306PubMedGoogle Scholar
  19. 19.
    Krepela E, Prochazka J, Karova B, Cermak J, Roubkova H (1998) Cysteine proteases and cysteine protease inhibitors in non-small cell lung cancer. Neoplasma 45:318–331PubMedGoogle Scholar
  20. 20.
    Kos J, Werle B, Lah T, Brunner N (2000) Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int J Biol Markers 15:84–89PubMedGoogle Scholar
  21. 21.
    Werle B, Schanzenbacher U, Lah TT et al (2006) Cystatins in non-small cell lung cancer: tissue levels, localization and relation to prognosis. Oncol Rep 16:647–655PubMedGoogle Scholar
  22. 22.
    Buttle DJ, Burnett D, Abrahamson M (1990) Levels of neutrophil elastase and cathepsin B activities, and cystatins in human sputum: relationship to inflammation. Scand J Clin Lab Invest 50:509–516PubMedCrossRefGoogle Scholar
  23. 23.
    Luthgens K, Ebert W, Trefz G, Gabrijelcic D, Turk V, Lah T (1993) Cathepsin B and cysteine proteinase inhibitors in bronchoalveolar lavage fluid of lung cancer patients. Cancer Detect Prev 17:387–397PubMedGoogle Scholar
  24. 24.
    Werle B, Sauckel K, Nathanson CM et al (2003) Cystatins C, E/M, and F in human pleural fluids of patients with neoplastic and inflammatory lung disorders. Biol Chem 382:281–287CrossRefGoogle Scholar
  25. 25.
    Warfel AH, Cardozo C, Yoo OH, Zucker-Franklin D (1991) Cystatin C and cathepsin B production by alveolar macrophages from smokers and nonsmokers. J Leukoc Biol 49:41–47PubMedGoogle Scholar
  26. 26.
    Altiok O, Yasumatsu R, Bingol-Karakoc G et al (2006) Imbalance between cysteine proteases and inhibitors in a baboon model of bronchopulmonary dysplasia. Am J Respir Crit Care Med 173:318–326PubMedCrossRefGoogle Scholar
  27. 27.
    Centers for Disease Control and Prevention (2010) NHANES–National Health and Nutrition Examination Survey homepage. Available at http://www.cdc.gov/nchs/nhanes.htm/. Accessed 3 August 2010
  28. 28.
    Levey AS, Coresh J, Balk E et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation classification and stratification. Ann Intern Med 139:137–147PubMedGoogle Scholar
  29. 29.
    Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298:2038–2047PubMedCrossRefGoogle Scholar
  30. 30.
    Selvin S, Manzi J, Stevens LA et al (2007) Calibration of serum creatinine in the National Health and Nutrition Examination Surveys (NHANES) 1988–1994, 1999–2004. Am J Kidney Dis 50:918–926PubMedCrossRefGoogle Scholar
  31. 31.
    Korkmaz B, Horwitz MS, Jenne DE, Gauthier F (2010) Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human disease. Pharmacol Rev 62:726–759PubMedCrossRefGoogle Scholar
  32. 32.
    Abrahamson M (1994) Cystatins. Methods Enzymol 244:685–700PubMedCrossRefGoogle Scholar
  33. 33.
    Salgado JV, Neves FA, Bastos MG et al (2010) Monitoring renal function: measured and estimated glomerular filtration rates—a review. Braz J Med Biol Res 43:528–536PubMedCrossRefGoogle Scholar
  34. 34.
    Lafarge JC, Naour N, Clement K, Guerre-Millo M (2010) Cathepsins and cystatin C in atherosclerosis and obesity. Biochimie 92:1580–1586PubMedCrossRefGoogle Scholar
  35. 35.
    Shlipak MG, Marnak MJ, Katz R et al (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060PubMedCrossRefGoogle Scholar
  36. 36.
    Finlay GA, Russell KJ, McMahon KJ et al (1997) Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 52:502–506PubMedCrossRefGoogle Scholar
  37. 37.
    Henskens YM, Veerman EC, Amerongen AV (1996) Cystatins in health and diseases. Biol Chem Hoppe Seyler 377:71–86PubMedGoogle Scholar
  38. 38.
    Abrahamson M, Alvarez-Fernandez M, Nathanson CM (2003) Cystatins. Biochem Soc Symp 70:179–199PubMedGoogle Scholar
  39. 39.
    Finkelstein R, Fraser RS, Ghezzo H, Cosio MG (1995) Alveolar inflammation and its relation to emphysema in smokers. Am J Respir Crit Care Med 152:1666–1672PubMedGoogle Scholar
  40. 40.
    Takeyabu K, Betsuyaku T, Nishimura M et al (1998) Cysteine proteinases and cystatin C in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Eur Respir J 12:1033–1039PubMedCrossRefGoogle Scholar
  41. 41.
    Chapman HA, Reilly JJ, Yee R, Grubb A (1990) Identification of cystatin C, a cysteine proteinase inhibitor, as a major secretory product of human alveolar macrophages in vitro. Am Rev Respir Dis 141:698–705PubMedCrossRefGoogle Scholar
  42. 42.
    Sloane BF, Rozhin J, Robinson D, Honn KV (1990) Role for cathepsin B and cystatins in tumor growth and progression. Biol Chem Hoppe Seyler 371:193–198PubMedGoogle Scholar
  43. 43.
    Woischnik M, Bauer A, Aboutaam R et al (2008) Cathepsin H and napsin A are active in the alveoli and increased in alveolar proteinosis. Eur Respir J 31:1197–1204PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of Internal MedicineCleveland ClinicClevelandUSA
  2. 2.Department of Cardiovascular MedicineCleveland ClinicClevelandUSA

Personalised recommendations